Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
oleh: Praveen K. Bommareddy, Samuel D. Rabkin, Howard L. Kaufman
| Format: | Article |
|---|---|
| Diterbitkan: | Taylor & Francis Group 2019-04-01 |
Deskripsi
In a recent edition of Science Translational Medicine, we identified an enhanced therapeutic activity when talimogene laherparepvec (T-VEC) was combined with MEK inhibition in murine melanoma tumor models. MEK inhibition increased viral replication independent of mutation status. Combination therapy increased PD-1/PD-L1 expression and PD-1 blockade further enhanced tumor regression. Further clinical development of this strategy for treating melanomas warranted.